Does cytoreductive surgery followed by adjuvant chemo-radiotherapy decrease the risk of recurrence and death in stage...

Area of Science:

• Gynecologic Oncology
• Surgical Oncology
• Radiation Oncology

Background:

• Optimal postoperative adjuvant treatment for stage III endometrial cancer (EC) remains controversial.
• Evaluating the impact of cytoreductive surgery (CRS) and adjuvant chemoradiotherapy (CRT) is essential for improving patient outcomes.

Purpose of the Study:

• To assess the effect of CRS and adjuvant CRT on relapse-free survival (RFS) and overall survival (OS) in patients with stage III EC.
• To identify prognostic factors influencing recurrence and survival in stage III EC.

Main Methods:

• Retrospective review of data from 36 patients with stage III EC.
• Analysis of surgical outcomes, including residual tumor status and adjuvant treatment modalities (CRT, RT, CT).
• Literature review to contextualize findings.

Main Results:

• Optimal cytoreduction (no residual tumor) was achieved in 88.9% of patients.
• Five-year RFS was 69.1% for CRT, 37.5% for RT, and 23.8% for CT (p=0.05).
• Five-year OS was 83% for CRT, 35.7% for RT, and 25% for CT (p=0.023). Residual tumor was an independent predictor of recurrence and death.

Conclusions:

• Optimal cytoreduction is the most significant prognostic factor in stage III EC.
• Adjuvant CRT is associated with a significant decrease in recurrence risk for stage III EC.
• Further research into the role of CRT in stage III EC is warranted.